Back to All Events

11th Annual Business of Regenerative Medicine: Innovation, Clinical Translation & Entrepreneurship Symposium


  • Smilow Center for Translational Research 3400 Civic Center Boulevard Philadelphia, PA, 19104 United States (map)

ARMI | BioFabUSA will be speaking at the 11th Annual Business of Regenerative Medicine: Innovation, Clinical Translation & Entrepreneurship Symposium.

ARMI Speakers will include:

Tom Bollenbach, Chief Technology Officer


The 11th annual Business of Regenerative Medicine: Innovation, Clinical Translation, and Entrepreneurship Symposium, a 2-day event with preceding evening reception and tour, will include lectures delivered by established entrepreneurs, industry and scientific leaders, panel discussions, networking events and more. It is attended by entrepreneurs, junior and senior scientists, business executives, investors and analysts, technology transfer and development personnel, managers in the government, non-profit and profit sectors.

The Symposium is hosted by the Center for Cellular Immunotherapies and the Institute for Regenerative Medicine at the University of Pennsylvania in partnership with Case Western Reserve University, the Harvard Stem Cell Institute, the Parker H. Petit for Institute Bioengineering and Bioscience at Georgia Tech, and the Centre for Commercialization of Regenerative Medicine.

PLANNED SESSIONS

  • The Stories of First In Class FDA Approved Gene Therapies Kymriah and Luxturna

  • Immune Cell Therapies: Where to Now?

  • Translating Regenerative Medicine

  • Regulatory and Ethical Foundation of Cellular and Tissue Based Therapies

  • Novel Applications of Mesenchymal Stromal Cells and Placental Derived Stem Cells

  • The Intersection of Engineering and Biology in the Creation of Novel Therapies

  • Operation of an Academic Cell Manufacturing Facility and Tech Transfer to Industry

  • Role of Academic Industry Government Consortia and Professional Societies

  • Intellectual Property and Licensing

  • Entrepreneurial Science and Commercialization